# ASC930 in Patients With Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)

> **NCT04883918** · PHASE2 · UNKNOWN · sponsor: **ASC Therapeutics** · enrollment: 60 (estimated)

## Conditions studied

- Acute-graft-versus-host Disease

## Interventions

- **BIOLOGICAL:** ASC930

## Key facts

- **NCT ID:** NCT04883918
- **Lead sponsor:** ASC Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-12
- **Primary completion:** 2026-01
- **Final completion:** 2026-04
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2023-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04883918

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04883918, "ASC930 in Patients With Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04883918. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*